Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\30013414
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Clin+Med+Insights+Endocrinol+Diabetes
2018 ; 11
(ä): 1179551418786258
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place
in Type 2 Diabetes Therapy
#MMPMID30013414
Goldman JD
Clin Med Insights Endocrinol Diabetes
2018[]; 11
(ä): 1179551418786258
PMID30013414
show ga
Type 2 diabetes mellitus (T2DM) is characterized by multiple metabolic
abnormalities and current approaches to treatment involve a stepwise approach,
frequently involving the use of combination therapy. The addition of the
sodium-glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, to metformin
therapy has been shown to be effective and well tolerated in patients with T2DM
and is 1 of the several recommended treatment options. The publication of the
EMPA-REG OUTCOME study, which showed that empagliflozin is associated with
cardiovascular (CV) and renal benefits, has resulted in changes in treatment
guidelines for T2DM. Because many patients with T2DM will require treatment with
more than 1 glucose-lowering agent, consideration of the role of empagliflozin in
combination therapy is relevant. The clinical data reviewed show that the
combination of empagliflozin/metformin offers the potential to improve glycemic
control in T2DM and reduces body weight and blood pressure, vs each agent
individually, with a manageable risk profile. This combination could be suitable
for patients with T2DM who are inadequately controlled by metformin, in
particular, for patients who would benefit from modest reductions in blood
pressure and body weight or who have risk factors for CV disease or declining
renal function. Empagliflozin/metformin is also available as a single-pill
combination, which has the potential to provide a simplified treatment regimen
and could lead to improved clinical outcomes compared with coadministration of
individual tablets.
free
free
free
